Dev R. Mehrotra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dev R. Mehrotra has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Michael B. Albro
College of Engineering, Boston University, Boston, MA, USA
5 shared publications - Brian D. Snyder
Boston Children's Hospital Boston Massachusetts USA
3 shared publications - Christian D. DeMoya
Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA
2 shared publications - Jacob J. Giering
College of Engineering, Boston University, Boston, MA
2 shared publications - Mark W. Grinstaff
Boston University
2 shared publications - Alberto Lalli
Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage
Modeling progressive pseudorheumatoid arthropathy of childhood: Disease progression and cartilage pathology in CCN6 knockout sheep
- 15 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage
Open AccessModeling progressive pseudorheumatoid arthropathy of childhood: Disease progression and cartilage pathology in CCN6 knockout sheep
- 17 June 2026
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (10) , 1461-1470
Multimodal characterization of articular cartilage degeneration in the humeral head using Raman spectroscopy, biomechanics, and imaging
- 17 June 2026
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (10) , 1461-1470
Multimodal characterization of articular cartilage degeneration in the humeral head using Raman spectroscopy, biomechanics, and imaging
- 15 December 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 212, 202-215
A sulfonated cartilage interpenetrating polymer network reinforces and protects the extracellular matrix of degraded cartilage
- 15 December 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 212, 202-215
A sulfonated cartilage interpenetrating polymer network reinforces and protects the extracellular matrix of degraded cartilage
- Open Access
A sulfonated cartilage interpenetrating polymer network reinforces and protects the extracellular matrix of degraded cartilage
Cartilage extracellular matrix (ECM) comprises a type-II collagen fibril network that affords structure and tensile strength, complemented by a negatively charged, sulfated glycosaminoglycan (GAG) matrix that retains interstitial water. These components act synergistically, bestowing the rheological and tribological material properties essential to cartilage function. At the onset of osteoarthritis, a disease characterized by cartilage degeneration, GAGs diminish from the ECM reducing interstitial fluid load support ( IFLS ) and transferring load to the collagen fibril network, which subsequently breaks down, culminating in increased hydraulic permeability, and decreased cartilage stiffness. We restore the material properties of damaged cartilage critical to diarthrodial joint function by forming an interpenetrating polymer network (IPN) with the native collagen using a synthetic, hydrophilic, and biocompatible GAG-mimetic polymer. Upon visible light activation, the monomer, 3-sulfopropylmethacrylate (SPM), and the crosslinker, polyethylene glycol diacrylate (PEGDA), form a sulfonated and anionic IPN that entangles and fills the existing porous degraded collagen matrix. Mechanistically, the highly sulfated, anionic SPM IPN retards water transport, reestablishes collagen fibril network integrity, and restores tissue IFLS , thereby returning the stiffness and viscoelastic properties of degraded cartilage to healthy levels. Additionally, the SPM IPN protects cartilage from further degradation by reducing the infiltration of inflammatory cytokines that upregulate catabolic matrix metalloproteinases and downregulate GAG production. Statement of significance: Amelioration of OA requires a comprehensive approach: neutralize or impede catabolic enzymes that degrade cartilage and reconstitute damaged cartilage by augmenting tissue ECM constituents. Currently, there are no clinical treatments that restore the viscoelastic material properties of hyaline cartilage tissue critical to its mechanical function and impart chondroprotection after OA induction. This work suggests that reconstituting GAG-depleted cartilage using a synthetic sulfonated interpenetrating polymer to reestablish IFLS that can be instilled into the joint and polymerized with white light during conventional arthroscopy represents a novel, minimally invasive, clinical treatment for early OA.
Open AccessA sulfonated cartilage interpenetrating polymer network reinforces and protects the extracellular matrix of degraded cartilage
Cartilage extracellular matrix (ECM) comprises a type-II collagen fibril network that affords structure and tensile strength, complemented by a negatively charged, sulfated glycosaminoglycan (GAG) matrix that retains interstitial water. These components act synergistically, bestowing the rheological and tribological material properties essential to cartilage function. At the onset of osteoarthritis, a disease characterized by cartilage degeneration, GAGs diminish from the ECM reducing interstitial fluid load support ( IFLS ) and transferring load to the collagen fibril network, which subsequently breaks down, culminating in increased hydraulic permeability, and decreased cartilage stiffness. We restore the material properties of damaged cartilage critical to diarthrodial joint function by forming an interpenetrating polymer network (IPN) with the native collagen using a synthetic, hydrophilic, and biocompatible GAG-mimetic polymer. Upon visible light activation, the monomer, 3-sulfopropylmethacrylate (SPM), and the crosslinker, polyethylene glycol diacrylate (PEGDA), form a sulfonated and anionic IPN that entangles and fills the existing porous degraded collagen matrix. Mechanistically, the highly sulfated, anionic SPM IPN retards water transport, reestablishes collagen fibril network integrity, and restores tissue IFLS , thereby returning the stiffness and viscoelastic properties of degraded cartilage to healthy levels. Additionally, the SPM IPN protects cartilage from further degradation by reducing the infiltration of inflammatory cytokines that upregulate catabolic matrix metalloproteinases and downregulate GAG production. Statement of significance: Amelioration of OA requires a comprehensive approach: neutralize or impede catabolic enzymes that degrade cartilage and reconstitute damaged cartilage by augmenting tissue ECM constituents. Currently, there are no clinical treatments that restore the viscoelastic material properties of hyaline cartilage tissue critical to its mechanical function and impart chondroprotection after OA induction. This work suggests that reconstituting GAG-depleted cartilage using a synthetic sulfonated interpenetrating polymer to reestablish IFLS that can be instilled into the joint and polymerized with white light during conventional arthroscopy represents a novel, minimally invasive, clinical treatment for early OA.
- 22 January 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (4) , 461-472
Raman spectroscopic probe provides optical biomarkers of cartilage composition predictive of tissue function
- 22 January 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (4) , 461-472
Raman spectroscopic probe provides optical biomarkers of cartilage composition predictive of tissue function